Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Research output: Contribution to journalJournal articleResearchpeer-review

Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.
Original languageEnglish
JournalCurrent Opinion in Pharmacology
Issue number6
Pages (from-to)589-96
Number of pages7
Publication statusPublished - 2004

Bibliographical note

Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Great Britain; Humans; Peptide Fragments; Protease Inhibitors; Protein Precursors

ID: 8417324